Stockscreener 앱 받기
7.95
4.45%
0.405
시간 외 거래:
7.95
전일 마감가:
$7.545
열려 있는:
$7.61
하루 거래량:
29,656
Relative Volume:
0.38
시가총액:
$73.56M
수익:
-
순이익/손실:
$-6.42M
주가수익비율:
-1.4193
EPS:
-5.6013
순현금흐름:
$-7.45M
1주 성능:
-0.25%
1개월 성능:
-9.31%
6개월 성능:
+34.25%
1년 성능:
+241.15%
1일 변동 폭
$7.61
$7.9586
1주일 범위
$7.43
$8.0001
52주 변동 폭
$1.92
$16.94
Cervomed Inc Stock (CRVO) Company Profile
명칭
Cervomed Inc
전화
(617) 744-4400
주소
20 PARK PLAZA, BOSTON
CRVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
7.95 | 69.81M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-13 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-12-05 | 개시 | H.C. Wainwright | Buy |
| 2024-09-18 | 개시 | Chardan Capital Markets | Buy |
| 2024-07-26 | 개시 | Morgan Stanley | Overweight |
| 2024-02-15 | 개시 | Canaccord Genuity | Buy |
| 2020-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Cervomed Inc 주식(CRVO)의 최신 뉴스
Is CervoMed Inc DP8 a good long term investmentMarket Sentiment Report & Learn From the Strategies of Institutions - earlytimes.in
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Will CervoMed Inc. stock see insider buyingVolume Analysis Techniques & Small Entry Cost Portfolio - bollywoodhelpline.com
Can CervoMed Inc. stock rebound after recent weakness2025 Market Overview & Risk Controlled Swing Alerts - Улправда
Will CervoMed Inc. (DP8) stock return to pre crash levels2025 Trading Volume Trends & Technical Pattern Based Signals - Улправда
What analyst consensus says on CervoMed Inc. stockStock Surge & Verified High Yield Trade Plans - Улправда
Is CervoMed Inc. stock vulnerable to regulatory risksEarnings Miss & Technical Analysis for Trade Confirmation - DonanımHaber
Aug Patterns: Will CervoMed Inc. stock gain from strong economyProduct Launch & AI Based Buy and Sell Signals - DonanımHaber
Why CervoMed Inc. (DP8) stock attracts wealthy investorsStop Loss & Advanced Technical Signal Analysis - DonanımHaber
Will CervoMed Inc. stock gain from strong economyWeekly Trend Recap & Daily Volume Surge Signals - Bölüm Sonu Canavarı
CervoMed (NASDAQ:CRVO) Receives Buy Rating from HC Wainwright - Defense World
Can CervoMed Inc. stock sustain institutional interest2025 Pullback Review & High Yield Equity Trading Tips - Улправда
Cantor Fitzgerald initiates CervoMed stock with Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald Initiates Coverage on CervoMed (CRVO) with Ove - GuruFocus
HC Wainwright Reaffirms Buy Rating for CervoMed (NASDAQ:CRVO) - MarketBeat
Cantor Fitzgerald Initiates Coverage on CervoMed With Overweight Rating - marketscreener.com
Cantor Fitzgerald initiates CervoMed stock with Overweight rating - Investing.com India
CervoMed Earnings Notes - Trefis
CEO Change: Is CervoMed Inc DP8 stock supported by strong fundamentals2025 Trading Volume Trends & Technical Pattern Based Signals - moha.gov.vn
New Highs: Can CervoMed Inc. stock rebound after recent weaknessJuly 2025 Gainers & Precise Swing Trade Entry Alerts - moha.gov.vn
Pleasing Signs As A Number Of Insiders Buy CervoMed Stock - Yahoo Finance
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2025-12-06 11:12:10 - moha.gov.vn
CervoMed Inc Announces New Data from RewinD-LB Trial - TradingView — Track All Markets
Today's Analyst Rating: CRVO Maintains "Buy" with $31 Price Targ - GuruFocus
Will CervoMed Inc. (DP8) stock benefit from Fed rate cutsJuly 2025 Intraday Action & Daily Volume Surge Signals - Newser
What RSI levels show for CervoMed Inc. (DP8) stockPortfolio Gains Report & Technical Confirmation Trade Alerts - Newser
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - The Manila Times
Why CervoMed Inc. (DP8) stock is a strong analyst pickEarnings Performance Report & Risk Managed Trade Strategies - Newser
Cervomed (CRVO) Unveils Promising Phase 2b Trial Results for Nef - GuruFocus
CervoMed’s DLB drug shows promise in phase 2b trial By Investing.com - Investing.com Nigeria
CervoMed’s DLB drug shows promise in phase 2b trial - Investing.com
CervoMed stock soars after promising dementia drug trial results By Investing.com - Investing.com South Africa
CervoMed stock soars after promising dementia drug trial results - Investing.com
CervoMed Inc. Reports Phase 2b RewinD-LB Trial Results for Neflamapimod, Showing Significant Improvements in Dementia with Lewy Bodies Patients - Quiver Quantitative
CervoMed Announces Late-Breaking Data at the 18th CTAD - GlobeNewswire
How rising interest rates impact CervoMed Inc. stockPortfolio Value Report & Safe Swing Trade Setups - Newser
Is CervoMed Inc. stock attractive after correctionJuly 2025 Action & Fast Exit and Entry Strategy Plans - Newser
Why CervoMed Inc. (DP8) stock stays undervaluedM&A Rumor & Short-Term High Return Strategies - Newser
CervoMed's (CRVO) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Neflamapimod reduces key neurodegeneration markers in DLB study By Investing.com - Investing.com Canada
CervoMed (NASDAQ:CRVO) Receives Buy Rating from D. Boral Capital - Defense World
CervoMed (CRVO) Maintains Buy Rating with Target Price of $31 | - GuruFocus
CervoMed (CRVO) Unveils Promising Phase 2b Trial Results for Alz - GuruFocus
Neflamapimod reduces key neurodegeneration markers in DLB study - Investing.com
Cervomed Inc (CRVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.53%
자본화:
|
볼륨(24시간):